MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-100372-PIP01-21

Scope of the Application

Active Substance(s)

concizumab

Condition(s)

Treatment of congenital haemophilia A, Treatment of congenital haemophilia B

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

Subcutaneous use

Name / Corporate name of the PIP applicant

Novo Nordisk Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Novo Nordisk Ltd submitted to the licensing authority on 24/01/2022 12:37 GMT an application for a Paediatric Investigation Plan

The procedure started on 12/08/2022 14:56 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100372-PIP01-21

Of 24/08/2022 09:23 BST

On the adopted decision for concizumab (MHRA-100372-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for concizumab, Solution for injection , Subcutaneous use .

This decision is addressed to Novo Nordisk Ltd, CMR, 3 City Place, Beehive Ring Road, Gatwick, United Kingdom, RH6 0PA

ANNEX I

1. Waiver

1.1 Condition:

Condition 1: Treatment of congenital haemophilia A Condition2: Treatment of congenital haemophilia B For both conditions, the waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age Pharmaceutical form(s): Solution for injection Route(s) of administration: Subcutaneous use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Condition 1: Treatment of congenital haemophilia A Condition: 2 Treatment of congenital haemophilia B

2.2 Indication(s) targeted by the PIP:

Condition 1: Prophylaxis of bleeding episodes in patients with congenital haemophilia A (factor VIII deficiency), with and without inhibitors Condition 2: Prophylaxis of bleeding episodes in patients with congenital haemophilia B (factor IX deficiency), with and without inhibitors

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

For both conditions: The paediatric population from 1 year to less than 18 years of age

2.4 Pharmaceutical Form(s):

For both conditions: Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable
Non-Clinical Studies	0	Not applicable
Clinical Studies	3	(Same studies for both conditions) Study 1 (NN7415-4311) Randomised, open label, active-control study to assess efficacy, safety and PK of concizumab prophylaxis as compared to no prophylaxis (bypassing agent on-demand) in patients with haemophilia A or B with inhibitors from 12 to less than 18 years of age (and adults). Study 2 (NN7415-4307) Randomised, open label, active-control study to assess efficacy, safety and PK of concizumab prophylaxis as compared to no prophylaxis (factor products on-demand) and to prophylaxis with factor VIII or factor IX in patients with congenital severe haemophilia A or moderate/ severe haemophilia B without inhibitors from 12 years to less than 18 years of age (and adults). Study 3 (NN7415-4616) Non-randomised, open-label, intra-patient controlled, single-arm study with age staggered enrolment to evaluate safety, efficacy and pharmacokinetics of concizumab prophylaxis versus previous standard of care on-demand and prophylaxis treatment in congenital haemophilia

		A and B with and without inhibitors, from 1 year to less than 12 years of age.
Extrapolation, Modeling & Simulation Studies	2	(Same studies for both conditions) Study 4 Population PK modelling and simulation study to evaluate a suitable dose of concizumab for children from 1 year to less than 18 years of age. Study 5 Exploratory analysis investigating the relationship between predicted concizumab exposure and treated bleeds.
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/01/2027
Deferral of one or more studies contained in the paediatric investigation plan:	Yes